Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. Issue 2 (15th July 2020)

• Record Type: Journal Article
• Authors: den Braanker, Hannah; Wervers, Kim; Mus, Adriana M C; Bangoer, Priyanka S; Davelaar, Nadine; Luime, Jolanda; Tchetverikov, Ilja; Hazes, J M W; Vis, Marijn; Lubberts, Erik; Kok, Marc R
• Is Part Of: RMD open. Volume 6:Issue 2(2020)
• Publication Date: 2020-07-15
• Subjects: Methotrexate -- Psoriatic Arthritis -- Cytokines -- Epidemiology; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2020-001175
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Objectives: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describes the response to MTX monotherapy in newly diagnosed patients with PsA in usual care. Second, we compared clinical variables and cytokine profiles in patients responding and not responding to MTX monotherapy. Methods: We used data collected in the Dutch southwest Early Psoriatic Arthritis cohoRt study to select patients with PsA with oligoarthritis or polyarthritis, and at least 1 year follow-up. We analysed disease activity at 6 months of patients who started MTX monotherapy and still used MTX monotherapy 1 year after diagnosis. Cytokine profiles were determined at baseline and after 3 and 6 months with a bead-based multi-immunoassay. Results: We identified 219 patients of which 183 (84%) patients started MTX monotherapy within 6 months after diagnosis. 90 patients used MTX monotherapy throughout the first year of which 44 patients (24%) reached minimal disease activity(MDA) at 6 months, decreasing to 33 patients (18%) after 1 year. Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy. Conclusions: Our results showed that only 18% of patients with PsA are in sustained MDA after 1 year of MTX monotherapy and non-responders more often had IL-23-driven disease. Our results indicate the need for more treat-to-target and personalised therapy strategies in PsA.